Tesamorelin
Also known as: Egrifta, TH9507
The only FDA-approved GHRH analog — clinically proven for visceral fat reduction.
Molecular structure image coming soon
Prescription only. FDA-approved brand is Egrifta. Available through compounding pharmacies with a prescription.
Overview
Tesamorelin is a synthetic GHRH analog that is FDA-approved for the treatment of HIV-associated lipodystrophy (excess visceral fat). It is the only GHRH peptide with full FDA approval and represents the gold standard of evidence for GHRH efficacy. Used off-label for general body composition improvement and GH optimization.
Mechanism of Action
Tesamorelin stimulates GHRH receptors in the pituitary, increasing GH production and IGF-1 levels. This leads to enhanced lipolysis (fat breakdown), particularly of visceral adipose tissue, as well as improved muscle metabolism.
Use Cases
- ✓Visceral fat reduction (FDA-approved for HIV lipodystrophy)
- ✓Body composition optimization (off-label)
- ✓Growth hormone optimization
- ✓Metabolic syndrome management
Research Summary
FDA approval was based on two Phase III randomized controlled trials demonstrating significant reductions in visceral adipose tissue in HIV+ patients. Multiple studies also show favorable body composition effects in non-HIV populations.
Typical Dosing
1–2 mg/day subcutaneous injection. FDA-approved dose: 2 mg/day.
Administration
Prescription Only
Prescription only. FDA-approved brand is Egrifta. Available through compounding pharmacies with a prescription.
